Evolus (NASDAQ:EOLS) Sets New 12-Month High – What’s Next?

Evolus, Inc. (NASDAQ:EOLS)’s stock price reached a new 52-week high during trading on Wednesday . The stock traded as high as $8.44 and last traded at $8.4140, with a volume of 99211 shares trading hands. The stock had previously closed at $8.18.

Analyst Ratings Changes

A number of equities analysts have recently weighed in on the company. BTIG Research restated a “buy” rating and issued a $13.00 target price on shares of Evolus in a research note on Wednesday, June 17th. Weiss Ratings raised Evolus from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Monday, June 15th. Finally, Wall Street Zen upgraded Evolus from a “hold” rating to a “buy” rating in a report on Saturday, August 8th. Four research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $14.50.

Evolus Stock Down 2.9%

The company has a market cap of $551.52 million, a P/E ratio of -16.06 and a beta of 1.35. The company’s 50-day moving average is $6.79 and its two-hundred day moving average is $5.75.

Institutional Investors Weigh In On Evolus

Several large investors have recently modified their holdings of EOLS. Rhumbline Advisers increased its holdings in Evolus by 2.0% in the 2nd quarter. Rhumbline Advisers now owns 85,093 shares of the company’s stock worth $784,000 after acquiring an additional 1,657 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in Evolus by 5.8% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 33,289 shares of the company’s stock valued at $400,000 after purchasing an additional 1,838 shares during the last quarter. Invesco Ltd. boosted its position in Evolus by 7.5% during the second quarter. Invesco Ltd. now owns 34,283 shares of the company’s stock worth $316,000 after purchasing an additional 2,383 shares during the period. Larson Financial Group LLC boosted its position in Evolus by 136.6% during the fourth quarter. Larson Financial Group LLC now owns 4,914 shares of the company’s stock worth $33,000 after purchasing an additional 2,837 shares during the period. Finally, Quantbot Technologies LP increased its stake in shares of Evolus by 15.4% in the second quarter. Quantbot Technologies LP now owns 29,731 shares of the company’s stock worth $274,000 after purchasing an additional 3,971 shares in the last quarter. Hedge funds and other institutional investors own 90.69% of the company’s stock.

About Evolus

Evolus, Inc is a specialty pharmaceutical company focused on medical aesthetics. Headquartered in Newport Beach, California, Evolus develops and commercializes products designed to enhance facial appearance through minimally invasive procedures. Since its founding in 2017, the company has positioned itself in the fast-growing aesthetic market by partnering with leading manufacturers and leveraging clinical expertise to bring innovative injectables to practitioners and patients.

The company’s flagship offering, Jeuveau (prabotulinumtoxinA-xvfs), is a neuromodulator approved by the U.S.